CL2018002462A1 - Composiciones farmacéuticas disuasivas del abuso. - Google Patents

Composiciones farmacéuticas disuasivas del abuso.

Info

Publication number
CL2018002462A1
CL2018002462A1 CL2018002462A CL2018002462A CL2018002462A1 CL 2018002462 A1 CL2018002462 A1 CL 2018002462A1 CL 2018002462 A CL2018002462 A CL 2018002462A CL 2018002462 A CL2018002462 A CL 2018002462A CL 2018002462 A1 CL2018002462 A1 CL 2018002462A1
Authority
CL
Chile
Prior art keywords
pharmaceutical compositions
deterring abuse
oxycodone
deterring
abuse
Prior art date
Application number
CL2018002462A
Other languages
English (en)
Inventor
Georg Gübitz
Katrin Greimel
Martin Brandauer
Daniela Huber
Klaus Bleymaier
Wolfgang Kroutil
Doris Lechner
Christof Wachter
Harald Wagner
Heimo Winkler
Original Assignee
G L Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G L Pharma Gmbh filed Critical G L Pharma Gmbh
Publication of CL2018002462A1 publication Critical patent/CL2018002462A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN OXICODONA Y UNA ENZIMA DE PROCESAMIENTO DE OXICODONA, EN DONDE LA OXICODONA ESTÁ CONTENIDA EN LA COMPOSICIÓN FARMACÉUTICA EN UN ESTADO REACTIVO A LA ENZIMA, ESTABLE AL ALMACENAMIENTO Y EN CONDICIONES EN DONDE NINGUNA ACTIVIDAD ENZIMÁTICA ACTÚA SOBRE LA OXICODONA.
CL2018002462A 2016-02-29 2018-08-28 Composiciones farmacéuticas disuasivas del abuso. CL2018002462A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16157803.4A EP3210630A1 (en) 2016-02-29 2016-02-29 Abuse-deterrent pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CL2018002462A1 true CL2018002462A1 (es) 2018-10-12

Family

ID=55446692

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002462A CL2018002462A1 (es) 2016-02-29 2018-08-28 Composiciones farmacéuticas disuasivas del abuso.

Country Status (10)

Country Link
US (2) US10702607B2 (es)
EP (2) EP3210630A1 (es)
JP (1) JP2019507178A (es)
CN (1) CN109104858A (es)
AU (1) AU2017226877A1 (es)
BR (1) BR112018067650A2 (es)
CA (1) CA3014007A1 (es)
CL (1) CL2018002462A1 (es)
MX (1) MX2018010435A (es)
WO (1) WO2017148924A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3210596A1 (en) * 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical composition

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852157A (en) 1971-05-14 1974-12-03 Syva Corp Compounds for enzyme amplification assay
JPS5327763A (en) * 1976-08-10 1978-03-15 Nissan Diesel Motor Co Ltd Pin-type synchronizer of auxiliary transmission
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4299916A (en) * 1979-12-26 1981-11-10 Syva Company Preferential signal production on a surface in immunoassays
IL68506A (en) * 1982-05-04 1988-06-30 Syva Co Simultaneous calibration heterogeneous immunoassay method and device and kit for use therein
DK77393D0 (da) 1993-06-29 1993-06-29 Novo Nordisk As Aktivering af enzymer
JP3691516B2 (ja) 1994-09-27 2005-09-07 ノボザイムス アクティーゼルスカブ アセトシリンゴンのような増強剤
AU1721697A (en) 1996-01-31 1997-08-22 Gist-Brocades B.V. Use of compositions comprising stabilized biologically effective compounds
ATE365208T1 (de) 1996-04-29 2007-07-15 Novozymes As Flüssige, nichtwässrige enzyme enthaltende zusammensetzungen
JP3320307B2 (ja) 1996-06-06 2002-09-03 株式会社エス・ディー・エス バイオテック フェノール性化合物等の高分子化方法及びその利用
GB9622516D0 (en) 1996-10-29 1997-01-08 Univ Cambridge Tech Enzymic cofactor cycling
JP2002520005A (ja) 1998-07-08 2002-07-09 ノボザイムス アクティーゼルスカブ タバコの処理におけるフェノール酸化酵素の利用
ATE238669T1 (de) 1998-11-09 2003-05-15 Novozymes As Antimikorbielle zusammensetzung, die eine oxidoreduktase und ein verstärkungsmittel vom n- hydroxyanilid-typ enthält
DE10029671A1 (de) 2000-06-23 2002-01-10 Frieder Schauer Biotransformation von biologisch aktiven Verindungen aus verschiedenen chemischen Stoffklassen mittels der Enzyme Laccase und Manganperoxidase
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7399488B2 (en) * 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
WO2004026283A1 (en) 2002-09-20 2004-04-01 Alpharma, Inc. Sequestering subunit and related compositions and metohds
JP2007525146A (ja) 2003-12-30 2007-09-06 ガムリンク エー／エス 生分解性ポリマーを含み且つ分解性を促進させたチューインガム
AU2012201450A1 (en) * 2004-11-24 2012-04-05 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
EP2028951B1 (en) 2006-06-16 2011-04-27 Gumlink A/S Chewing gum comprising a hydrophobic enzyme formulation
US8158156B2 (en) 2006-06-19 2012-04-17 Alpharma Pharmaceuticals, Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US20080075771A1 (en) 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic opioid abuse deterrent delivery system using opioid antagonists
DE102006048833A1 (de) 2006-10-16 2008-04-17 Universität Rostock Behandlung von Osteoporose
EP2101740B1 (en) * 2006-12-04 2013-11-06 Orexo AB New non-abusable pharmaceutical composition comprising opioids
US7999104B2 (en) * 2007-06-29 2011-08-16 Brock University Methods for one-pot N-demethylation/N-acylation of morphine and tropane alkaloids
US20110262359A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
RU2555042C2 (ru) 2010-07-02 2015-07-10 Дзе Проктер Энд Гэмбл Компани Способ доставки активнодействующего вещества
EP2635258A1 (en) 2010-11-04 2013-09-11 AbbVie Inc. Drug formulations
WO2012085016A1 (de) 2010-12-20 2012-06-28 Cytec Austria Gmbh Verfahren zur härtung von oberflächenbeschichtungsmitteln
WO2012096886A1 (en) * 2011-01-11 2012-07-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
ES2584634T3 (es) 2011-01-11 2016-09-28 Signature Therapeutics, Inc. Composiciones que comprenden un profármaco de oxicodona escindible enzimáticamente
AU2012219322A1 (en) * 2011-02-17 2013-05-09 QRxPharma Ltd. Technology for preventing abuse of solid dosage forms
CA2827662C (en) 2011-03-09 2020-07-14 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
IN2014DN03009A (es) 2011-10-26 2015-05-08 Kempharm Inc
FR2983409B1 (fr) * 2011-12-06 2013-12-27 Ethypharm Sa Comprime susceptible de lutter contre le detournement par voie injectable
AU2013352162B2 (en) 2012-11-30 2018-08-16 Acura Pharmaceuticals, Inc. Self-regulated release of active pharmaceutical ingredient
JP6198495B2 (ja) 2013-07-12 2017-09-20 キヤノン株式会社 画像形成装置
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill

Also Published As

Publication number Publication date
AU2017226877A1 (en) 2018-08-23
CN109104858A (zh) 2018-12-28
BR112018067650A2 (pt) 2019-04-09
JP2019507178A (ja) 2019-03-14
US20190060470A1 (en) 2019-02-28
EP3423101A1 (en) 2019-01-09
US20200261585A1 (en) 2020-08-20
CA3014007A1 (en) 2017-09-08
US10702607B2 (en) 2020-07-07
WO2017148924A1 (en) 2017-09-08
MX2018010435A (es) 2019-05-22
EP3210630A1 (en) 2017-08-30

Similar Documents

Publication Publication Date Title
MX2021004479A (es) Agentes biologicos y su uso en plantas.
CL2016002772A1 (es) Composiciones de insulina de rápida acción
BR112017014230A2 (pt) endófitos de semente através de cultivares e espécies, composições associadas e métodos de uso dos mesmos
AU366476S (en) Bottle
AR102074A1 (es) Composiciones de limpieza que comprenden polialquileniminas alcoxiladas y copolímeros que contienen grupos sulfonato
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
MY192705A (en) Compositions and methods for treating anemia
AU363980S (en) Container with stacking tabs
CL2015002897A1 (es) Inhibidores de bace1
MA40460A (fr) Ciblage lysosomial et utilisation correspondante
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
AU364385S (en) Bottle
CL2017000072A1 (es) Detergente en tabletas para lavavajillas, métodos de fabricación y uso del mismo
CL2018002463A1 (es) Composición farmacéutica disuasiva del abuso.
EP3378060A4 (en) DETECTION OF ASYNCHRONOUS CLAIM IN TEXT-BASED NEWS
CL2018002462A1 (es) Composiciones farmacéuticas disuasivas del abuso.
NZ713440A (en) Nsaid administration and related compositions, methods and systems.
EA201790915A1 (ru) Титрованные экстракты cynara scolymus для применения в лечении мезотелиомы
AU364472S (en) Bottle
CL2018002461A1 (es) Composiciones farmacéuticas disuasivas del abuso.
WO2014186344A3 (en) Methods and agents for treating tyrosinase-positive albinism
CL2018000308A1 (es) Composiciones en microcápsulas que comprenden pirimetanilo
GB2543709A (en) Pharmaceutical agent
UA118032U (uk) Фармацевтична композиція